Form 4: Cabaletta Bio CFO Anup Marda Granted Stock Options

Anup Marda, CFO of Cabaletta Bio, Inc., was granted stock options for 130,000 shares on March 1, 2024, according to a Form 4 filing with the SEC.

Summary

• Anup Marda, the Chief Financial Officer of Cabaletta Bio, Inc. (CABA), was granted stock options on March 1, 2024.
• The options give Marda the right to buy 130,000 shares of Cabaletta Bio's common stock at an exercise price of $23.97 per share.
• 25% of the options will vest on March 1, 2025, and the remaining options will vest in twelve substantially equal quarterly installments thereafter, contingent upon Marda's continued service.
• The options expire on February 28, 2034.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to stock option grants, which is neutral in sentiment.

Positives

• The granting of stock options to the CFO aligns their interests with those of the shareholders.
• The vesting schedule incentivizes the CFO to remain with the company.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock options are a common form of compensation for executives in publicly traded companies, particularly in the biotechnology industry, to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Comparable companies like Juno Therapeutics (acquired by Celgene) and Kite Pharma (acquired by Gilead) have used similar stock option plans to incentivize their executives.
• The vesting schedule and exercise price are typical for such grants, designed to reward long-term value creation.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.
• The grant incentivizes the CFO to work towards increasing shareholder value.

Key Dates